4-(cyclohexylcarbamoyloxy)benzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(cyclohexylcarbamoyloxy)benzoic acid
• 化学式: C₁₄H₁₇NO₄
• 分子量: 263.293
• InChiKey: VEKBZKLOABNYDW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 生成 4-(cyclohexylcarbamoyloxy)benzoic acid
  参考文献：
  名称：

  DE2050087

  摘要：

  公开号：

文献信息

• IONIZABLE INHIBITORS OF FATTY ACID AMIDE HYDROLASE
  申请人：Dasse Olivier

  公开号：US20070155707A1

  公开（公告）日：2007-07-05

  Pharmacological inhibition of fatty acid amide hydrolase (FAAH) activity leads to increased levels of fatty acid amides. Esters of alkylcarbamic acids are disclosed that are inhibitors of FAAH activity. Compounds disclosed herein inhibit FAAH activity. Described herein are processes for the preparation of esters of alkylcarbamic acid compounds, compositions that include them, and methods of use thereof.

  药理学上抑制脂肪酸酰胺水解酶（FAAH）活性会导致脂肪酸酰胺水平升高。本文披露了烷基氨基甲酸酯类化合物，可作为FAAH活性抑制剂。本文披露的化合物可抑制FAAH活性。本文还描述了制备烷基氨基甲酸酯类化合物的过程，包括它们的组成成分和使用方法。
• METHODS FOR DETERMINING EFFECTIVE DOSES OF FATTY ACID AMIDE HYDROLASE INHIBITORS IN VIVO
  申请人：Compton R. Timothy

  公开号：US20080089845A1

  公开（公告）日：2008-04-17

  Described herein is a method for determining an effective dose of a composition for inhibiting fatty acid amide hydrolase activity in vivo, by first administering to a subject a dose of a test composition, and subsequently assessing if the level of a fatty acid amide in the subject increases. Also described, is a method for optimizing therapeutic efficacy for treatment of anxiety, depression, pain, or a metabolic disorder by increasing or decreasing a dose of a fatty amide hydrolase inhibitor according to a patient's fatty acid amide levels. In addition, pharmaceutical compositions are described, which contain fatty acid amide hydrolase inhibitors effective for increasing a FAA level in a patient.
• [EN] IONIZABLE INHIBITORS OF FATTY ACID AMIDE HYDROLASE<br/>[FR] INHIBITEURS IONISABLES D'AMIDE D'ACIDE GRAS HYDROLASE
  申请人：ORGANON NV

  公开号：WO2008020866A1

  公开（公告）日：2008-02-21

  [EN] Pharmacological inhibition of fatty acid amide hydrolase (FAAH) activity leads to increased levels of fatty acid amides. Esters of alkylcarbamic acids are disclosed that are inhibitors of FAAH activity. Compounds disclosed herein inhibit FAAH activity. Described herein are processes for the preparation of esters of alkylcarbamic acid compounds, compositions that include them, and methods of use thereof.
  [FR] L'inhibition pharmacologique de l'activité amide d'acide gras hydrolase (FAAH) conduit à des taux accrus d'amides d'acides gras. L'invention concerne des esters d'acides alkylcarbamiques qui sont des inhibiteurs de l'activité FAAH. Les composés selon l'invention inhibent l'activité FAAH. L'invention concerne également des procédés pour la préparation d'esters de composés d'acides alkylcarbamiques, des compositions qui les comprennent et des procédés permettant de les utiliser.
• [EN] METHODS FOR DETERMINING EFFECTIVE DOSES OF FATTY ACID AMIDE HYDROLASE INHIBITORS IN VIVO<br/>[FR] PROCÉDÉS DE DÉTERMINATION DES DOSES EFFICACES DES INHIBITEURS DE L'AMIDE D'ACIDE GRAS-HYDROLASE IN VIVO
  申请人：ORGANON NV

  公开号：WO2008030752A2

  公开（公告）日：2008-03-13

  [EN] Described herein is a method for determining an effective dose of a composition for inhibiting fatty acid amide hydrolase activity in vivo, by first administering to a subject a dose of a test composition, and subsequently assessing if the level of a fatty acid amide in the subject increases. Also described, is a method for optimizing therapeutic efficacy for treatment of anxiety, depression, pain, or a metabolic disorder by increasing or decreasing a dose of a fatty amide hydrolase inhibitor according to a patient's fatty acid amide levels. In addition, pharmaceutical compositions are described, which contain fatty acid amide hydrolase inhibitors effective for increasing a FAA level in a patient.
  [FR] La présente invention concerne un procédé de détermination de la dose efficace d'une composition destinée à inhiber une activité amide d'acide gras-hydrolase in vivo, en administrant d'abord à un sujet une dose d'une composition testée et en recherchant ensuite si le taux d'un amide d'acide gras a augmenté chez le sujet. L'invention concerne également un procédé permettant d'optimiser l'efficacité thérapeutique pour le traitement de l'angoisse, de la dépression, de la douleur ou d'une affection métabolique en augmentant ou en diminuant la dose d'un inhibiteur d'amide d'acide gras-hydrolase en fonction des taux d'amides d'acide gras chez le patient. De plus, l'invention concerne des compositions pharmaceutiques qui contiennent des inhibiteurs d'amide d'acide gras-hydrolase efficaces pour augmenter le taux de FAA (Fatty Acid Amide : amide d'acide gras) chez un patient.
• DE2050087
  申请人：——

  公开号：——

  公开（公告）日：——